Promoted Content

Promoted Content

All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Grifols International

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SPAIN Spain

Post An Enquiry

Biofit 2020

Participation Not Confirmed

Update your events

Results of Grifols' AMBAR Clinical Trial Published in Alzheimer's & Dementia

Contact the Supplier

Lead Product(s): Perflutren,Immunoglobulin G 285-292

Therapeutic Area: Neurology Product Name: Albutein

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 27, 2020

Details:

Previously presented at various medical congresses, AMBAR findings demonstrate a slowdown in the progression of symptoms in patients with mild-to-moderate Alzheimer's.